Elsevier, Neuropathology of Aging and Alzheimer's Disease, 2025, pp 163-176
This content aligns with Goal 3: Good Health and Wellbeing and Goal 9: Industry, Innovation, and Infrastructure by exploring a novel area of research exploring the link between vascular disease and Alzheimer's Disease.
Elsevier, Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease, Volume 1, Seventh Edition, 2025, pp 99-113
This content aligns with Goal 3: Good Health and Wellbeing and Goal 9: Industry, Innovation, and Infrastructure by discussing the role of genetic variants found to affect cholinergic and noncholinergic neurotransmission.
Elsevier, Tryptamine Microbiota-Deregulated Aminoacyl-tRNA Biosynthesis: A Conceptual Evolution of the Role of Microbiota Tryptamine in Human Diseases, 2024, pp 253-267
This content aligns with Goal 3: Good Health and Wellbeing and Goal 9: Industry, Innovation, and Infrastructure by highlighting the data demonstrating the role tryptamine plays in Alzheimer's Disease.
Elsevier, Heavy Metal Toxicity and Neurodegeneration, 2025, pp 225-230
This content aligns with Goal 3: Good Health and Wellbeing and Goal 9: Industry, Innovation, and Infrastructure by considering the role heavy metals such as lead, mercury, and cadmium can play in Alzheimer's Disease.
Elsevier, Natural Molecules in Neuroprotection and Neurotoxicity, 2024, pp 1669-1678
This content aligns with Goal 3: Good Health and Wellbeing and Goal 9: Industry, Innovation, and Infrastructure by identifying potential nutraceutical applications of bioactive compounds for prevention and treatment of Alzheimer's Disease.
Elsevier, Novel Drug Delivery Systems in the management of CNS Disorders, 2025, pp 199-214
This content aligns with Goal 3: Good Health and Wellbeing and Goal 9: Industry, Innovation, and Infrastructure by examining novel medications and drug delivery systems to advance the treatment of Alzheimer's Disease.
Elsevier, Essential Guide to Neurodegenerative Disorders: Mechanistic, Diagnostic and Therapeutic Advances, 2025, pp 3-15
This content aligns with Goal 3: Good Health and Wellbeing and Goal 9: Industry, Innovation, and Infrastructure by discussing the roles of Tau, glial, and amyloid (A) in Alzheimer's Disease development.
Elsevier, Nutraceutical Fruits and Foods for Neurodegenerative Disorders, 2024, pp 379-404
This content aligns with Goal 3: Good Health and Wellbeing and Goal 9: Industry, Innovation, and Infrastructure by considering the neuroprotective properties of nutraceuticals such as soy, peanuts, and ginsenoside Rg1.
Elsevier, Handbook of Clinical Neurology, Volume 211, 2025, pp 63-79
This content aligns with Goal 3: Good Health and Wellbeing and Goal 9: Industry, Innovation, and Infrastructure by providing an overview of the cholinergic hypothesis of Alzheimer's Disease and potential innovations in cholinergic therapies.
Elsevier, Microbiota-Gut-Brain Axis and CNS Disorders: Recent Progress and Perspectives, 2025, pp 19-41
This content aligns with Goal 3: Good Health and Wellbeing and Goal 9: Industry, Innovation, and Infrastructure by discussing the understudied impacts of the gut microbiome and chronic inflammation that may contribute to neurodegeneration.